Supercharged immune cells take aim at myeloma

NCT ID NCT02291848

Ongoing Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This early-stage trial tests whether specially trained immune cells can safely target and attack multiple myeloma, as well as its early forms MGUS and smoldering myeloma. Up to 36 participants will receive two infusions of their own T cells that have been engineered to recognize five proteins found on cancer cells. The main goal is to find the safest dose and watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAA-specific cytotoxic T-lymphocytes (immune cells)
What this could lead to: If it works, this could point toward a new way to control multiple myeloma or stop early forms from progressing.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, so it may not work or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance plasma cell myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Harris Health Ben Taub Hospital

Houston, Texas, 77030, United States
Harris Health Smith Clinic

Houston, Texas, 77030, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.